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Background and aims: In REMOVAL, metformin reduced the rate of progression of the tertiary carotid 
outcome (averaged maximal cIMT) over three years in middle-aged adults with longstanding type 1 
diabetes but did not significantly reduce progression of the primary outcome (averaged mean cIMT). We 
now report subgroup analyses for the primary outcome (the only subgroup analyses that were pre-
specified). 
Materials and methods: 3-way interaction terms with treatment and time were calculated for the 
following baseline variables: age, duration of diabetes, baseline HbA1c, BMI, LDL cholesterol, systolic 
BP (all by above or below median), baseline cIMT (by tertiles), sex (male or female), smoking (ever or 
never), insulin pump user (yes or no) and history of cardiovascular disease (present or absent). 
Results: The 3-way interaction term was significant for only one of the 11 pre-specified subgroup 
analyses: smoking status (p=0·0373). Of 428 randomised participants, [(mean±SD) age 55±8·5 years, 
HbA1c 8·0±0·82%, BMI 28·4±4·3 kg/m², 59% male, duration of diabetes 34±10·8 years, 12% with a 
history of cardiovascular disease, 82% on statin therapy], 227 (53%) were never smokers, 144 (34%) 
were ex-smokers and 57 (13%) were current smokers. Mean±SD duration of smoking was 22±13·2 years. 
The primary outcome mean cIMT was reduced by metformin in the 227 never smokers (-0·012 mm per 
year, 95% CI -0·021 to -0·002; p=0·0137) but not in the 201 ever smokers (0·003 mm per year, 95% CI -
0·008 to 0·014; p=0·5767). 
Conclusion: While subgroup analyses should be treated with caution, these data suggest that metformin 
may reduce progression of mean carotid IMT in type 1 diabetes in the absence of the powerful 
cardiovascular risk factor of smoking. This provides further support for a wider role of metformin in 
cardiovascular risk management. 
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